TEVA PHARMACEUTICAL INDUSTRIES LIMITED Research and Development in Process
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) reported Research and Development in Process of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-02-10
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED research and development in process for the quarter ending 2021-12-31 was $10.00M, a 75.00% decline year-over-year.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED research and development in process for the quarter ending 2020-12-31 was $40.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED research and development in process for the quarter ending 2019-12-31 was $0.00.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED research and development in process for the quarter ending 2009-12-31 was $23.00M, a 97.68% decline year-over-year.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED research and development in process for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED research and development in process for fiscal 2021 was $10.00M, a 87.50% decline from fiscal 2020.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED research and development in process for fiscal 2020 was $80.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED research and development in process for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-10 | |||
| 2021-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $10.00M 10-K · filed 2023-02-10 | ||
| 2021-09-30 | $0.00 10-Q · filed 2021-10-27 | |||
| 2020-12-31 | $40.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $80.00M 10-K · filed 2023-02-10 | ||
| 2020-09-30 | $40.00M 10-Q · filed 2021-10-27 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $0.00 10-K · filed 2022-02-09 | ||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $114.00M 10-K · filed 2021-02-10 | |||
| 2010-09-30 | $9.00M 6-K · filed 2010-11-02 | |||
| 2009-12-31 | $23.00M derived: 20-F 12 month − 6-K 9 month · filed 2010-02-22 | $23.00M derived: sum of 2 quarters · filed 2010-02-22 | $23.00M derived: sum of 3 quarters · filed 2010-02-22 | $23.00M 20-F · filed 2010-02-22 |
| 2009-09-30 | $0.00 6-K · filed 2009-11-03 | $0.00 derived: sum of 2 quarters · filed 2009-11-03 | $0.00 6-K · filed 2010-11-02 | $992.00M derived: sum of 4 quarters · filed 2010-02-22 |
| 2009-06-30 | $0.00 6-K · filed 2009-07-29 | $0.00 6-K · filed 2009-07-29 | $992.00M derived: sum of 3 quarters · filed 2010-02-22 | $1.02B derived: sum of 4 quarters · filed 2010-02-22 |
| 2009-03-31 | $0.00 6-K · filed 2009-05-07 | $992.00M derived: sum of 2 quarters · filed 2010-02-22 | $1.02B derived: sum of 3 quarters · filed 2010-02-22 | $1.02B derived: sum of 4 quarters · filed 2010-02-22 |
| 2008-12-31 | $992.00M derived: 20-F 12 month − 6-K 9 month · filed 2010-02-22 | $1.02B derived: sum of 2 quarters · filed 2010-02-22 | $1.02B derived: sum of 3 quarters · filed 2010-02-22 | $1.40B 20-F · filed 2010-02-22 |
| 2008-09-30 | $28.00M 6-K · filed 2009-11-03 | $28.00M derived: sum of 2 quarters · filed 2009-11-03 | $410.00M 6-K · filed 2009-11-03 | |
| 2008-06-30 | $0.00 6-K · filed 2009-07-29 | $382.00M 6-K · filed 2009-07-29 | ||
| 2008-03-31 | $382.00M 6-K · filed 2009-05-07 | |||
| 2007-12-31 | $0.00 20-F · filed 2010-02-22 |